Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05376319 · ClinicalTrials.gov registry record · Phase 2
PR3-AAV Resilient Remission or PRRR
A Phase 2 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT05376319: Clinical Trial Phase 2 study, sponsored by Mayo Clinic.
NCT05376319 is a Phase 2 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05376319, a Phase 2 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of obinutuzumab for the treatment of proteinase 3 Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (PR3-AAV).
Interventions
- DRUG Obinutuzumab
- DRUG Rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2023-06-30 |
| Est. Completion | 2024-05-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05376319
The ClinicalTrials.gov registry entry for NCT05376319 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Obinutuzumab is the first listed.
NCT05376319 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05376319 about?
NCT05376319 is a clinical study titled "PR3-AAV Resilient Remission or PRRR". The purpose of this study is to evaluate the efficacy and safety of obinutuzumab for the treatment of proteinase 3 Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (PR3-AAV).
What is the current status of trial NCT05376319?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2023-06-30. Estimated completion is 2024-05-07.
What interventions are being tested in trial NCT05376319?
The interventions under investigation include: Obinutuzumab (DRUG), Rituximab (DRUG).
Who is sponsoring clinical trial NCT05376319?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.